Targeting Ras in Myeloid Leukemias: Fig. 1.

Targeting Ras in myeloid leukemias.

Ras proteins normally relay growth-promoting signals from many activated cell surface receptors, and they are altered by oncogenic point mutations in approximately 30% of human cancers. Activating KRAS and NRAS mutations are especially common in malignancies of the pancreas, lung, and colon, and in myeloid leukemia. Here, we discuss general strategies for targeting hyperactive Ras signaling in ...

Therapy-Related Acute Myeloid Leukemias

Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous group of myeloid neo‐ plasms occurring as an overwhelming complication in patients receiving previous cytotoxic chemotherapy and/or radiation therapy used to treat haematopoietic or solid malignancies or associated with immunosuppressive treatment for non-neoplastic rheumatologic/autoim‐ mune diseases or solid organ transplantati...

G-csf and Myeloid Leukemias

Various cytokines play roles in the process of granulocytic proliferation, differentiation and maturation from hemopoietic stem/progenitor cells and in the functional activation of mature granulocytes. Among these cytokines, the most essential is granulocyte colony-stimulating factor (G-CSF), which is a 19KD glycoprotein composed of 174 amino acids with one o-linked sugar chain. This molecule i...

Classification of acute myeloid leukemias

Modulation of nitrosourea resistance in myeloid leukemias.

Drug resistance in myeloid leukemias may be mediated by an increased capacity to repair chemotherapy-induced DNA damage. Some tumor cell lines that are resistant to nitrosoureas contain the DNA repair protein O6-alkylguanine-DNA alkyltransferase (alkyltransferase). This protects cells by removing cytotoxic, nitrosourea-induced O6-alkylguanine adducts. We measured the level of alkyltransferase a...